Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Current Deferred Revenue (2022 - 2023)

Avalo Therapeutics (AVTX) has disclosed Current Deferred Revenue for 2 consecutive years, with $111000.0 as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Current Deferred Revenue changed N/A year-over-year to $111000.0, compared with a TTM value of $111000.0 through Mar 2023, changed N/A, and an annual FY2022 reading of $88000.0, changed N/A over the prior year.
  • Current Deferred Revenue was $111000.0 for Q1 2023 at Avalo Therapeutics, up from $88000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $400000.0 in Q3 2022 and bottomed at $88000.0 in Q4 2022.